A Study of the Safety and Efficacy of Nitric Oxide Reduction in Patients With Cardiogenic Shock After a Heart Attack

NCT00112281 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

658

Enrollment

INDUSTRY

Sponsor class

Conditions

Shock, Cardiogenic

Interventions

DRUG: Tilarginine Acetate Injection intravenous infusion

Sponsor

Arginox Pharmaceuticals